Future of basic/clinical hematopoiesis research in the era of hematopoietic growth factor availability.
Bernstein
S H
SH
Department of Hematological Oncology, Roswell Park Cancer Institute, Buffalo, NY.
Kufe
D W
DW
D000818:Animals; D054407:Chemokine CCL4; D016207:Cytokines / Q000627:therapeutic use; D006131:Growth Inhibitors / Q000627:therapeutic use; D006410:Hematopoiesis; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use; D015850:Interleukin-6 / Q000627:therapeutic use; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000627:therapeutic use; D019402:Macrophage Inflammatory Proteins; D015846:Monokines / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D019089:Stem Cell Factor
D054407:Chemokine CCL4; D016207:Cytokines; D006131:Growth Inhibitors; D016298:Hematopoietic Cell Growth Factors; D007375:Interleukin-1; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D019402:Macrophage Inflammatory Proteins; D015846:Monokines; D011993:Recombinant Fusion Proteins; D019089:Stem Cell Factor